BoB Sponsors

BoB Sponsors

BoB Platinum Sponsor: Shire

Shireis now the leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions.

These diseases are often misunderstood, undiagnosed and life-threatening. We have best-in-class products available in more than 100 countries across core therapeutic areas including Hematology, Immunology, Oncology, Neuroscience, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine and Hereditary Angioedema. Of the 22,000 employees worldwide, 4,000 work in Vienna and Orth on the Danube. Thus Austria is an important Shire location.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

BoB Gold Sponsor: Roche ​​​​

Roche is second time sponsor of BoB Best of Biotech businessplan competition. ​​

About Roche​​​

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.​​

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.​​

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.​​

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit​​

Roche in Austria​​​

Roche is one of Austria's leading suppliers of innovative pharmaceutical products and precise diagnostic services. ​​

In 2015 Roche employed approximately 400 people in Austria. The three independent affiliates from Roche (Roche Austria GmbH, Roche Diagnostics GmbH, Roche Diabetes Care GmbH) are located in Vienna. ​​

Roche leads the overall Austrian pharmaceutical market and is number one in the hospital market, in cancer drugs and in almost all in-vitro diagnostic devices and tests that are available in Austria. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to the right patient at the right time. ​​

For more information on Roche in Austria, please visit our website​​

BoB Silver Sponsor: Boehringer Ingelheim

Boehringer Ingelheimis one of the world’s twenty leading pharmaceutical companies​​

Headquartered in Ingelheim, Germany, it operates globally with around 47,500 employees. The focus of the family-owned company is research, development, production, and marketing of new medications of high therapeutic value for human and veterinary medicine. The Boehringer Ingelheim Regional Center Vienna is responsible for Boehringer Ingelheim’s human pharmaceutical and animal health business in Austria as well as the clinical research in more than thirty countries in Central and Eastern Europe and Central Asia. It is the center for cancer research and a biopharmaceutical research, development and production hub within the international group. Boehringer Ingelheim is involved in basic research through the Research Institute of Molecular Pathology (IMP) in Vienna. This makes it the most research intensive pharmaceutical company in Austria. In 2015, the Regional Center Vienna employed 3,403 people, including 1,501 in Austria.​​

BoB Medtech Award Sponsor: LISAvienna​​​​

LISAvienna sponsors the LISAvienna Medtech Award.


LISAvienna is the joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry of Science, Research and Economy and the city of Vienna, it contributes to the advancement of life sciences in Vienna. LISAvienna supports innovative biotech, pharmaceutical and medical technology companies in Vienna that develop and market new products, services and processes. The platform links these companies with development partners and key customers. As a central knowledge carrier, LISAvienna provides input for decisions to advance the life sciences in Vienna and contributes to positioning the city of Vienna as one of the leading European innovation centers.​​​​


  • Information & Consulting: Tips and contacts relating to sponsorship, private financing options, infrastructure in Vienna, development partners, leading customers and internationalization
  • Networking & Matching: Contacts for an improved exchange of experiences and knowledge transfer as well as contact with development partners, leading customers and investors worldwide
  • Expertise: Analyses, background information, reports and studies relating to life sciences in Vienna
  • Marketing: Electronic and printed news items from the field of life sciences in Vienna​

BoB Sponsor: Standortagentur Tirol​​​​

Standortagentur Tirol is sponsoring BoB for the 6th time!​​​​

As location agency of Tirol, the develops, promotes and markets the Tirolean economy and science. Thereto it encourages the transfer of new technologies from Tirolean research institutions into the economy and connects Tirolean companies with research establishments. It supports the development of important economic fields in clusters and directly promotes projects in cooperative research and technology. ​​​​

Furthermore, the Tiroler Zukunftsstiftung initiates and finances programs for education and advanced training, tailored to the needs of companies in sunrise industries. It also encourages the development as well as the settlement and the start of companies and research institutions in the business location through professional consultation and support. The Tiroler Zukunftsstiftung connects economy, science and politics. The Tirolean companies are the main beneficiaries of its work.​​​​